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addressing the uncertainty about the 
safety of thiazolidinediones. Nevertheless, 
these observations underline the diﬃculty 
in determining the full safety proﬁle of a 
drug before its approval for marketing. 
Meanwhile, a United States federal advi-
sory panel said that rosiglitazone should 
remain on the market because its beneﬁts 
outweigh the risks, and studies concern-
ing the safety of the drug were too gloomy 
to impose drastic restriction to its market. 
Moreover, risks associated with rosiglita-
zone might be no worse than those of other 
diabetes medicines.  
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Genetic complexity in Joubert 
syndrome and related disorders
PC Harris1
The recent identification of RPGRIP1L as a Joubert syndrome gene brings 
the total of known genes to five. Three of these are also associated with 
the lethal Meckel syndrome, and two with Senior–Løken syndrome; both 
of these disorders share Joubert syndrome phenotypes, illustrating the 
genetic complexity of this.
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Joubert syndrome is an autosomal recessive 
disorder characterized by cerebellar ver-
mis hypoplasia, recognized by a distinctive 
brainstem malformation, the ‘molar tooth 
sign’ seen radiologically; abnormal eye 
movements; hypotonia; and development 
delay/mental retardation. Around a quar-
ter of patients also have nephronophthisis 
(NPHP, consisting of tubulointerstitial ﬁbro-
sis and cysts at the corticomedullary junc-
tion) and retinal dystrophy, which is termed 
Joubert syndrome type B, or cerebello-
oculo-renal syndrome (CORS). A number 
of other clinical abnormalities are found 
in Joubert syndrome and related disorders 
(JSRD), including occipital encephalocele, 
polymicrogyria, cystic kidneys, polydactyly, 
hepatic ﬁbrosis, and ocular coloboma. Sev-
eral of these phenotypes are similar to those 
associated with the lethal, recessive disorder 
Meckel syndrome (MKS), which is charac-
terized by renal cystic dysplasia, occipital 
encephalocele (or other central nervous 
system phenotypes), polydactyly, and 
hepatic ﬁbrosis. A group of related disor-
ders is recessively inherited isolated NPHP 
with an infantile, juvenile, or adolescent 
time at end-stage renal disease, which can 
also be associated with retinitis pigmentosa 
(Senior–Løken syndrome; SLS). Positional 
cloning studies in the past few years have 
revealed considerable genetic heterogeneity 
and genetic relatedness of these diseases.
Joubert syndrome has an approximately 
described incidence in the United States 
of 1 in 100,000, and five gene loci have 
been described: AHI1 (6q23.3),1 NPHP1 
(2q13),2 CEP290/NPHP6 (12q21.3),3 MKS3 
(8q22.1),4 and RPGRIP1L (16q12.2),5,6 
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(Table 1) with two others linked to chro-
mosome regions (9q34 and 11q2–q13) but 
not identiﬁed. The high level of genetic het-
erogeneity is similar to that of NPHP (seven 
genes identified) and MKS (four genes 
identiﬁed). AHI1 is thought to account for 
10%–15% of cases of JSRD, and CEP290 
is estimated to cause a similar proportion 
of such cases. Homozygous deletion of 
NPHP1 is responsible for 1%–2% of JSRD, 
and one study found MKS3 mutations in 
4 of 22 JSRD patients.4 RPGRIP1L is the 
most recently identified JSRD (CORS) 
gene that was recognized by two separate 
groups.5,6 Both used a genome-wide single-
nucleotide polymorphism array linkage 
approach in consanguineous families and 
found a region of homozygosity on 16q that 
contained a good candidate on the basis of 
functional data (see below). This interval 
was syntenic with the mouse model Fused 
toes (Ft). Ft/Ft embryos die at mid-gesta-
tion with exencephaly, polydactyly, and 
laterality defects.5,7,8 These initial studies 
found mutations in nine JSRD families. 
Wolf and colleagues9 (this issue) have now 
extended the mutation analysis of that locus 
in Joubert syndrome type B patients (nega-
tive for AHI1 and CEP290 mutations), and 
5 of 56 had RPGRIP1L mutations. Two new 
cases were homozygous for a previously 
deﬁned missense change, T615P, and one 
homozygous for a novel change, C633R. In 
two further cases, just one likely mutation 
was found, a typical splicing change, IVS23-
2A→G or the missense change E393K. 
Overall, these studies show that RPGRIP1L 
is a signiﬁcant cause of JSRD.
The RPGRIP1L protein has been local-
ized to the basal body-centrosome and 
ciliary axoneme and colocalized with the 
NPHP proteins NPHP4 and NPHP6.5,6 
RPGRIP1L is a homologue of the retinitis 
pigmentosa GTPase regulator-interacting 
protein, RPGRIP1, which is a cause of 
Leber congenital amaurosis.10 RPGRIP1 
has been localized to the connecting cil-
ium of photoreceptors and also interacts 
with NPHP4 through a protein kinase C 
conserved region (C2 domain) that is 52% 
identical to that found in RPGRIP1L.11 
RPGRIP1L consists of five coiled-coil 
domains in the N-terminal part of the pro-
tein, a C-terminal region with homology 
to the RPGR-interacting domain, and two 
central C2 domains. It appears to be widely 
expressed in the organs involved in JSRD.
A common feature of proteins involved 
in JSRD, NPHP, MKS, the related Bardet–
Biedl syndrome (which involves vision 
loss, mental retardation, renal disease, 
polydactyly, and obesity), and orofaci-
odigital (craniofacial abnormalities, poly-
dactyly, and polycystic kidney disease) is 
the localization of causative proteins to 
the basal body-centrosome and in some 
cases to the axoneme of the cilium.12–14 
The pleiotropic phenotypes associated 
with this collection of diseases are thought 
to be due to defective ciliary function and 
hence have been classed as ciliopathies. 
Primary cilia are thought to play an impor-
tant sensory and mechanosensory role that 
links external cues to maintenance of the 
normal cellular diﬀerentiated state. Mech-
anosensation through the autosomal domi-
nant polycystic kidney disease (ADPKD) 
protein (polycystin) complex is thought 
to be important for maintaining tubular 
diﬀerentiation in the kidney and liver, and 
defective cilia in the photoreceptor cells or 
the embryonic node result in retinal defects 
or laterality defects, respectively. Recently, 
important developmental pathways such as 
Hedgehog signaling and the non-canonical 
Wnt pathway have been linked with cilia 
and may underlie many of the develop-
ment abnormalities (for example, poly-
dactyly and exencephaly) associated with 
these disorders.15 Recently, a downstream 
eﬀector of the Hedgehog pathway, GLIS2, 
was found to be defective in NPHP.16
The phenotypic overlap between JSRD 
and NPHP and MKS is reflected in the 
overlap of the genes that have been iden-
tified in these disorders. In three cases, 
CEP290, MKS3, and RPGRIP1L, genes 
associated with JSRD are also found in 
patients with the lethal MKS.5,17–19 Like-
wise, two JSRD genes, NPHP1 and CEP290, 
are also associated with isolated NPHP 
and SLS.19,20 Allelic eﬀects may be impor-
tant for the severity of the phenotype, as 
a tendency for two probably inactivat-
ing mutations in MKS3 and RPGRIP1L 
is associated with MKS, and at least one 
possible hypomorphic allele (a missense 
change or atypical splicing event) is often 
found in patients with JSRD.4,9 However, 
this tendency does not explain all of the 
phenotypic penetrance, as a homozygous 
deletion (1721delA) and a homozygous 
typical splicing change (2305-1G→A) to 
RPGRIP1L are associated with a viable 
JSRD phenotype.6 In the case of CEP290, 
allelic eﬀects seem less compelling, since 
many cases with two apparent truncating 
mutations are associated with a viable phe-
notype,20 as well as with MKS,18,19 which 
indicates that other genetic (and environ-
mental) factors are also probably inﬂuenc-
ing the phenotype.
In several cases of JSRD associated with 
RPGRIP1L or CEP290 mutation, only a 
single likely mutation has been identi-
fied.9,20 This may simply reflect missed 
mutations that are not detected by the typi-
cal screen for base-pair changes in exonic 
regions. However, it suggests that oligo-
genic inheritance may also play a role in 
this disorder. In the highly genetically het-
erozygous Bardet–Biedl syndrome, oligo-
genic inheritance, with mutations involving 
more than one gene and the involvement of 
three mutant alleles, is important in some 
Table 1 | Details of Joubert syndrome and related disorders (JSRD) genes and proteins
Gene Joubert syndrome phenotypea Other disease associations Protein location
NPHP1 CVH, NPHP, OMA NPHP, SLS Cell–cell/matrix
AHI1 CVH, RD ?
CEP290 MR, NPHP, LCA SLS, NPHP, MKS Centrosome/cilia 
MKS3 CVH, MR, RM, DPM MKS Cilia/basal body/centrosome
RPGRIP1L CVH, MR, NPHP, OMA MKS Basal body/cilia
aMajor phenotypes detected: CVH, cerebellar vermis hypoplasia; DPM, ductal plate malformation; LCA, Leber congenital amaurosis; RM, renal microcysts; MKS, Meckel syndrome; 
MR, mental retardation/development delay; NPHP, nephronophthisis; OMA, ocular motor apraxia; RD, retinal dystrophy.
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cases for disease development22, 23 and has 
also recently been described in NPHP. 24 
The increasing number of JSRD genes, the 
variable phenotype only partly associated 
with genic and allelic eﬀects, plus cases 
with missing mutations, indicate that this 
step toward complex inheritance is also a 
possibility in JSRD.
The overlapping phenotypes of JSRD, 
MKS, NPHP, and SLS, plus the overlap-
ping group of genes involved in causing 
these diseases, highlight deficiencies in 
the existing forms of disease classiﬁcation. 
Although the phenotypic description of a 
family is clearly what initially determines 
the disease classiﬁcation and focuses the 
search for the molecular cause, it is limited 
as a ﬁnal disease classiﬁer. Increasingly, 
it will be important to base the disease 
classiﬁcation on the gene that is mutated. 
Although this is complicated by allelic 
eﬀects, genetic background, and possible 
other complex inheritance, it is the most 
logical basis for classifying genetic diseases 
and an essential starting point for compre-
hensive genotype–phenotype studies.
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Thiazide diuretic monotherapy 
for hypertension: Diuretic’s dark 
side just got darker
BH Rovin1 and LA Hebert1
Diuretic monotherapy is the current recommendation of the Joint 
National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure for initial antihypertensive 
therapy. There is mounting concern, however, that the benefits 
of diuretic’s superior blood pressure control may be offset by its 
multiple metabolic disturbances that increase cardiovascular risk. 
Reungjui et al. document a new concern, nephrotoxicity by thiazide 
monotherapy. This and other recently published evidence of 
diuretic’s ‘dark side’ is discussed.
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In this issue of Kidney International, 
Reungjui and colleagues1 convincingly 
show that chronic hydrochlorothiazide 
administration causes focal glomeru-
lar and tubular interstitial injury in 
rats independent of diuretic-induced 
hypokalemia, hyperglycemia, hype-
ruricemia, and blood pressure (BP) 
changes. This work adds signiﬁcantly 
to the list of ‘metabolic dysfunctions’ of 
thiazide diuretic2 that could negate the 
cardiovascular and renal beneﬁts expected 
